FDA submissions, 510(k), premarket evidence, and security testing. Based on the FDA's February 3, 2026 premarket cybersecurity guidance.
Medical device cybersecurity protects a device, its software, and its connected systems so attackers cannot harm patients, disrupt therapy, or expose data. It covers secure design, threat modeling, testing, software inventories, and vulnerability management across the device's life. Patient safety comes first.
FDA cybersecurity refers to the evidence the FDA reviews in a premarket submission and the lifecycle duties that follow. Section 524B sets statutory duties for cyber devices. The FDA's February 3, 2026 guidance describes the agency's current recommendations for the documentation.
Cybersecurity evidence can apply across these pathways. The content depends on the device, its connectivity, and the submission type. An IDE has different expectations than a marketing submission, so confirm scope with your regulatory team.
Read each request closely, map it to the missing evidence, and answer it directly. Blue Goat responds in 30 days or less from kickoff, once we have the FDA letter, your documentation, and any test access we need. The FDA decides the outcome.
Monitor your SBOM for new vulnerabilities, assess each one against your device, coordinate disclosure, and plan updates. Legacy devices may need compensating controls when updates are limited.
The guidance recommends testing tied to your threat model, including penetration testing, with documented scope, methods, findings, and retests. A software bill of materials supports vulnerability analysis.
The applicable evidence depends on your device, risks, and submission pathway. The FDA's February 3, 2026 premarket guidance recommends documentation covering secure development, threat modeling, cybersecurity risk assessment, architecture, software components, security testing, labeling, and vulnerability management. Section 524B imposes separate statutory obligations for covered cyber-device submissions. Identify applicability before assembling the evidence.
No. Applicability depends on the statutory cyber-device definition and the submission type. The definition includes sponsor-validated, installed, or authorized software, the ability to connect to the internet, and technological characteristics that could be vulnerable to cybersecurity threats. Assess the device and its connected system rather than assuming a device class or wireless interface alone settles applicability.
No. Guidance describes the FDA's current recommendations and generally does not establish legally enforceable responsibilities. Section 524B contains statutory duties for covered submissions. Keep legal obligations, guidance recommendations, and device-specific evidence decisions distinct in your planning.
Review the exact question, identify the evidence gap, and coordinate a response with your regulatory and engineering teams. A response may need revised documentation, additional testing, or updated traceability. Blue Goat provides cybersecurity deficiency-response support. The FDA decides the submission outcome; responding to a question does not establish acceptance.
Cybersecurity evidence is included in the applicable sections and attachments of your 510(k), not treated as a separate marketing submission. Organize documents so the device version, architecture, threats, controls, and test results can be traced together. Your regulatory team owns the submission and its device-specific applicability decisions.
Predicate information can provide context, but it does not replace evidence for your device. Review differences in software, connectivity, architecture, intended use, security controls, and component support. Your threat model and testing should describe the device version and ecosystem being submitted.
Use the applicable cybersecurity fields and attachments in the current eSTAR template. Keep document names, versions, identifiers, and cross-references consistent. Explain exclusions and unresolved findings rather than treating an uploaded document as proof that a requirement has been met.
Start during design and development so the threat model informs security requirements and architecture. Plan testing around a representative device build, available inputs, and time for engineering fixes and retests. Waiting until the submission date to begin can leave little time to address findings.
The package coordinates the agreed threat modeling, cybersecurity risk assessment, security architecture, SBOM work, security testing, labeling, and vulnerability management planning. Scope is defined for your device and pathway, with a fixed fee after scoping. It is cybersecurity work, not general software testing or software validation.
Yes. The threat model identifies attack paths and controls; the cybersecurity hazard analysis supplies patient-harm context. Blue Goat reviews these inputs during scoping. Missing documentation or deeper rework is separately agreed before testing begins.
No. An SBOM inventories software components. A vulnerability assessment examines known vulnerabilities and their relevance to the device. A component match alone does not establish exploitability. VEX conclusions need status-specific technical evidence and manufacturer review.
Automated scanning can identify known weaknesses, but it does not replace adversarial testing of device-specific attack paths. Manual testing examines authorization, clinical workflow abuse, trust boundaries, and vulnerability chains. The agreed scope and report should document methods, access, limitations, and results.
You receive the Test Plan, Test Cases, and Test Report. They document tester independence and expertise, scope, duration, methods, findings, and retest evidence, with traceability to threats and security requirements. A letter of attestation is not needed for FDA penetration testing.
Yes. Standalone testing includes the agreed dynamic and adversarial checks, testing documents, and retests. SAST, software composition analysis, SBOM work, and threat-model rework are separate unless explicitly bundled. Choose the broader package when you need documentation and security activities coordinated together.
The schedule depends on the device, connected components, available documentation, access, and work still needed. Agree separate milestones for readiness, testing, reporting, engineering fixes, and retests. A submission date is a planning input, not a guarantee of testing completion or clearance.
Yes. Blue Goat includes unlimited retests until every finding with uncontrolled risk is closed within the agreed device versions and interfaces. Your engineers implement fixes; we verify them and update evidence. Risk disposition and any residual-risk acceptance remain documented manufacturer decisions.
No. Manufacturers need lifecycle processes for monitoring vulnerabilities, evaluating risk, coordinating disclosures, and developing and communicating updates. The applicable duties depend on the device and regulatory context. Premarket planning should connect to those postmarket activities.
Use the FDA cybersecurity FAQ for detailed regulatory topics and the compliance roadmap to organize your reading across FDA, EU, and ISO resources. Device-specific questions should be reviewed with your regulatory team.
30-minute strategy session. No cost, no commitment - just answers from people who've supported 275+ FDA submissions, with zero cybersecurity rejections.
